Therapeutic
Area Expertise

therapeutic-expertise-Ico

Expertise in oncology and inflammatory
chronic diseases

Amgen is steeped in the science of creating, producing, and manufacturing life-changing medicines. Throughout our long history in oncology and inflammation, we have brought novel and practice-changing supportive and therapeutic biologics to patients with serious diseases. We are now applying that experience to developing our biosimilar medicines.

therapeutic-scientific-icon

Scientific know-how

We have deep knowledge of the science of creating and producing biologic drugs, which are significantly more variable and structurally complex than chemically synthesized drugs.1

therapeutic-patient-icon

There for every Amgen patient,
every time

Amgen has not had a product shortage in 10 years, ensuring every patient's needs are met, every time. We have nearly four decades of experience producing high-quality biologics—and a determination to get medication to every Amgen patient, every time. We look forward to continuing this record of quality and reliability with our biosimilars.

References: 1. Health Canada Guidance Document: Information and Submission Requirements for Biosimilar Biologic Drugs. Accessed May 24, 2018. Available at: https://www.canada.ca/content/dam/hc-sc/migration/hc-sc/dhp-mps/alt_formats/pdf/brgtherap/applic-demande/guides/seb-pbu/seb-pbu-2016-eng.pdf. 2. Health Canada. Biosimilar Biologic Drugs in Canada: Fact Sheet. Accessed September 18, 2019. Available at: https://www.canada.ca/content/dam/hc-sc/migration/hc-sc/dhp-mps/alt_formats/pdf/brgtherap/applic-demande/guides/Fact-Sheet-EN-2019-08-23.pdf.

Next: Biologics Development

previous: Quality Assurance